X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)
EnEPC-CLI-01
Phase 2 small_molecule active
Quick answer
X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza) for Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment. is a Phase 2 program (small_molecule) at Biogen Idec Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Biogen Idec Ltd
- Indication
- Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active